Harmony Biosciences Holdings annual debt-to-equity ratio
2020
2021
2022
2023
2024
2025
Harmony Biosciences Holdings Debt-to-Equity Ratio Growth & History (HRMY)
Harmony Biosciences Holdings's debt-to-equity ratio was 0.19 for fiscal 2025.
View full Harmony Biosciences Holdings company overviewHarmony Biosciences Holdings annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.19 | −0.08 | −29.33% |
| 2024 | 2024-12-31 | 0.28 | −0.14 | −34.46% |
| 2023 | 2023-12-31 | 0.42 | −0.06 | −12.92% |
| 2022 | 2022-12-31 | 0.48 | −0.57 | −54.06% |
| 2021 | 2021-12-31 | 1.05 | −0.95 | −47.49% |
| 2020 | 2020-12-31 | 2.00 | — | — |
Harmony Biosciences Holdings quarterly debt-to-equity ratio
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.16 | −0.06 | −28.52% |
| Q1 2026 | 2026-03-31 | 0.18 | −0.07 | −26.59% |
| Q4 2025 | 2025-12-31 | 0.19 | −0.08 | −29.33% |
| Q3 2025 | 2025-09-30 | 0.20 | −0.11 | −34.52% |
| Q2 2025 | 2025-06-30 | 0.22 | −0.13 | −36.11% |
| Q1 2025 | 2025-03-31 | 0.25 | −0.13 | −34.25% |
| Q4 2024 | 2024-12-31 | 0.28 | −0.14 | −34.46% |
| Q3 2024 | 2024-09-30 | 0.31 | −0.10 | −25.19% |
| Q2 2024 | 2024-06-30 | 0.35 | −0.05 | −12.09% |
| Q1 2024 | 2024-03-31 | 0.37 | −0.06 | −14.53% |
| Q4 2023 | 2023-12-31 | 0.42 | −0.06 | −12.92% |
| Q3 2023 | 2023-09-30 | 0.41 | −0.15 | −26.72% |
| Q2 2023 | 2023-06-30 | 0.40 | −0.39 | −49.56% |
| Q1 2023 | 2023-03-31 | 0.44 | −0.47 | −51.90% |
| Q4 2022 | 2022-12-31 | 0.48 | −0.57 | −54.06% |
| Q3 2022 | 2022-09-30 | 0.57 | −0.70 | −55.19% |
| Q2 2022 | 2022-06-30 | 0.79 | −0.75 | −48.78% |
| Q1 2022 | 2022-03-31 | 0.91 | −0.90 | −49.57% |
| Q4 2021 | 2021-12-31 | 1.05 | −0.95 | −47.49% |
| Q3 2021 | 2021-09-30 | 1.26 | −0.78 | −38.06% |
| Q2 2021 | 2021-06-30 | 1.55 | — | — |
| Q1 2021 | 2021-03-31 | 1.81 | — | — |
| Q4 2020 | 2020-12-31 | 2.00 | — | — |
| Q3 2020 | 2020-09-30 | 2.04 | — | — |
Harmony Biosciences Holdings debt-to-equity ratio trends
Over the last five fiscal years, Harmony Biosciences Holdings's debt-to-equity ratio decreased from 2.00 to 0.19, a change of −1.80. The latest reported quarter, Q2 2026, shows 0.16.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Harmony Biosciences Holdings source filings ↗